Trade Inovio Pharmaceuticals, Inc. - INO CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.0400 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Inovio Pharmaceuticals Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 0.36 |
Open* | 0.3599 |
1-Year Change* | -80.12% |
Day's Range* | 0.3575 - 0.3783 |
52 wk Range | 0.38-2.61 |
Average Volume (10 days) | 2.11M |
Average Volume (3 months) | 140.51M |
Market Cap | 120.74M |
P/E Ratio | -100.00K |
Shares Outstanding | 268.08M |
Revenue | 9.62M |
EPS | -0.66 |
Dividend (Yield %) | N/A |
Beta | 0.97 |
Next Earnings Date | Nov 6, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 29, 2023 | 0.3675 | 0.0075 | 2.08% | 0.3600 | 0.3783 | 0.3575 |
Sep 28, 2023 | 0.3600 | -0.0060 | -1.64% | 0.3660 | 0.3677 | 0.3535 |
Sep 27, 2023 | 0.3611 | 0.0006 | 0.17% | 0.3605 | 0.3650 | 0.3570 |
Sep 26, 2023 | 0.3576 | -0.0077 | -2.11% | 0.3653 | 0.3658 | 0.3576 |
Sep 25, 2023 | 0.3600 | 0.0000 | 0.00% | 0.3600 | 0.3600 | 0.3500 |
Sep 19, 2023 | 0.3900 | 0.0000 | 0.00% | 0.3900 | 0.3900 | 0.3900 |
Sep 18, 2023 | 0.3900 | 0.0000 | 0.00% | 0.3900 | 0.3900 | 0.3900 |
Sep 15, 2023 | 0.4000 | -0.0100 | -2.44% | 0.4100 | 0.4100 | 0.4000 |
Sep 14, 2023 | 0.3900 | -0.0100 | -2.50% | 0.4000 | 0.4000 | 0.3900 |
Sep 13, 2023 | 0.4100 | -0.0100 | -2.38% | 0.4200 | 0.4300 | 0.4100 |
Sep 12, 2023 | 0.4300 | -0.0100 | -2.27% | 0.4400 | 0.4400 | 0.4300 |
Sep 11, 2023 | 0.4300 | 0.0000 | 0.00% | 0.4300 | 0.4300 | 0.4300 |
Sep 8, 2023 | 0.4300 | -0.0100 | -2.27% | 0.4400 | 0.4400 | 0.4100 |
Sep 7, 2023 | 0.4300 | -0.0200 | -4.44% | 0.4500 | 0.4600 | 0.4200 |
Sep 6, 2023 | 0.4100 | -0.0200 | -4.65% | 0.4300 | 0.4300 | 0.4100 |
Sep 5, 2023 | 0.4300 | 0.0000 | 0.00% | 0.4300 | 0.4400 | 0.4200 |
Sep 1, 2023 | 0.4300 | 0.0000 | 0.00% | 0.4300 | 0.4400 | 0.4300 |
Aug 31, 2023 | 0.4300 | 0.0000 | 0.00% | 0.4300 | 0.4400 | 0.4300 |
Aug 30, 2023 | 0.4300 | 0.0000 | 0.00% | 0.4300 | 0.4300 | 0.4200 |
Aug 29, 2023 | 0.4300 | 0.0200 | 4.88% | 0.4100 | 0.4300 | 0.4100 |
Inovio Pharmaceuticals, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Monday, November 6, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q3 2023 Inovio Pharmaceuticals Inc Earnings Release Q3 2023 Inovio Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Wednesday, February 28, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q4 2023 Inovio Pharmaceuticals Inc Earnings Release Q4 2023 Inovio Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 10.2623 | 1.77476 | 7.41122 | 4.11193 | 30.4819 |
Revenue | 10.2623 | 1.77476 | 7.41122 | 4.11193 | 30.4819 |
Total Operating Expense | 277.836 | 302.993 | 126.787 | 115.22 | 124.573 |
Selling/General/Admin. Expenses, Total | 90.1853 | 53.7523 | 37.2478 | 27.2032 | 29.3152 |
Research & Development | 187.65 | 249.24 | 94.2454 | 88.0173 | 95.2579 |
Unusual Expense (Income) | 0 | 0 | -4.70606 | 0 | 0 |
Operating Income | -267.574 | -301.218 | -119.376 | -111.109 | -94.0911 |
Interest Income (Expense), Net Non-Operating | -6.21775 | -2.34978 | -42.8094 | -10.1968 | -0.70688 |
Net Income Before Taxes | -277.653 | -303.224 | -162.89 | -120.809 | -94.798 |
Net Income After Taxes | -277.653 | -303.224 | -162.89 | -120.552 | -96.9678 |
Minority Interest | 0 | 0 | 1.06376 | 1.19256 | |
Net Income Before Extra. Items | -279.818 | -303.659 | -166.411 | -119.359 | -96.9678 |
Net Income | -279.818 | -303.659 | -166.411 | -119.359 | -96.9678 |
Income Available to Common Excl. Extra. Items | -279.818 | -303.659 | -166.411 | -119.359 | -96.9678 |
Income Available to Common Incl. Extra. Items | -279.818 | -303.659 | -166.411 | -119.359 | -96.9678 |
Diluted Net Income | -279.818 | -303.659 | -166.411 | -119.359 | -96.9678 |
Diluted Weighted Average Shares | 238.622 | 208.83 | 155.127 | 98.718 | 92.54 |
Diluted EPS Excluding Extraordinary Items | -1.17264 | -1.4541 | -1.07274 | -1.20909 | -1.04785 |
Diluted Normalized EPS | -1.17264 | -1.4541 | -1.10308 | -1.20909 | -1.04785 |
Total Extraordinary Items | |||||
Other, Net | -3.86158 | 0.34337 | -0.7049 | 0.4962 | |
Equity In Affiliates | -2.16521 | -0.43439 | -4.58461 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0.22597 | 0.11494 | 0.12467 | 9.15413 | 0.7844 |
Revenue | 0.22597 | 0.11494 | 0.12467 | 9.15413 | 0.7844 |
Total Operating Expense | 37.2671 | 44.0671 | 56.0708 | 44.9112 | 104.922 |
Selling/General/Admin. Expenses, Total | 13.5231 | 13.8906 | 13.9509 | 11.824 | 48.4568 |
Research & Development | 21.744 | 30.1765 | 42.1199 | 33.0871 | 56.4649 |
Operating Income | -37.0411 | -43.9522 | -55.9462 | -35.757 | -104.137 |
Interest Income (Expense), Net Non-Operating | 2.93443 | 5.72854 | 4.2473 | -1.08608 | -4.35694 |
Other, Net | -1.42787 | -2.42568 | -2.76429 | -0.94078 | -0.00305 |
Net Income Before Taxes | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
Net Income After Taxes | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
Minority Interest | 0 | ||||
Equity In Affiliates | 0 | 0 | 0 | 0 | 0 |
Net Income Before Extra. Items | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
Net Income | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
Income Available to Common Excl. Extra. Items | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
Income Available to Common Incl. Extra. Items | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
Diluted Net Income | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
Diluted Weighted Average Shares | 264.354 | 258.438 | 250.585 | 249.351 | 235.278 |
Diluted EPS Excluding Extraordinary Items | -0.13442 | -0.15729 | -0.21734 | -0.15153 | -0.46114 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.12685 | -0.15729 | -0.21734 | -0.15153 | -0.46114 |
Unusual Expense (Income) | 2 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 315.243 | 448.445 | 471.171 | 94.201 | 87.8148 |
Cash and Short Term Investments | 252.999 | 401.315 | 411.643 | 89.5341 | 81.2325 |
Cash & Equivalents | 46.3294 | 71.1438 | 250.728 | 22.1961 | 23.6936 |
Short Term Investments | 206.669 | 330.171 | 160.915 | 67.338 | 57.5388 |
Total Receivables, Net | 11.7382 | 8.03204 | 19.0637 | 2.03212 | 4.05494 |
Accounts Receivable - Trade, Net | 1.70173 | 5.46685 | 18.56 | 0.70007 | 3.31636 |
Prepaid Expenses | 50.5057 | 39.0982 | 40.4639 | 2.63474 | 2.5274 |
Total Assets | 348.533 | 495.941 | 539.772 | 143.952 | 131.113 |
Property/Plant/Equipment, Total - Net | 17.9562 | 29.0242 | 24.0894 | 26.556 | 15.949 |
Property/Plant/Equipment, Total - Gross | 39.5196 | 47.9686 | 40.083 | 39.7225 | 25.9489 |
Accumulated Depreciation, Total | -21.5634 | -18.9444 | -15.9936 | -13.1665 | -9.99992 |
Goodwill, Net | 10.5134 | 10.5134 | 10.5134 | 10.5134 | 10.5134 |
Intangibles, Net | 2.12986 | 2.62636 | 3.14677 | 3.69385 | 4.76015 |
Long Term Investments | 2.00714 | 3.9068 | 4.89475 | 6.31536 | 9.40591 |
Other Long Term Assets, Total | 0.68404 | 1.42579 | 25.9575 | 2.67202 | 2.67 |
Total Current Liabilities | 96.8681 | 65.7416 | 41.706 | 31.9893 | 35.2998 |
Accounts Payable | 19.8625 | 24.2137 | 0.82552 | 6.91908 | 10.0438 |
Payable/Accrued | 45.2204 | 0.54803 | 0.64297 | 0.72973 | 4.60189 |
Accrued Expenses | 29.2224 | 36.3611 | 32.658 | 17.4428 | 15.1386 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 2.5627 | 4.61885 | 7.57944 | 6.89777 | 5.51547 |
Total Liabilities | 126.171 | 96.2721 | 78.6317 | 140.516 | 44.1771 |
Total Long Term Debt | 16.6148 | 14.9597 | 18.6558 | 77.0229 | 0 |
Deferred Income Tax | 0.03205 | 0.03205 | 0.03205 | 0.03205 | 0.02477 |
Minority Interest | 0 | 1.96976 | 0.09627 | ||
Other Liabilities, Total | 12.6556 | 15.5387 | 18.2379 | 29.5025 | 8.75633 |
Total Equity | 222.363 | 399.669 | 461.141 | 3.4351 | 86.9361 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.25309 | 0.21738 | 0.18685 | 0.10136 | 0.09723 |
Additional Paid-In Capital | 1710.66 | 1609.59 | 1367.41 | 742.647 | 707.794 |
Retained Earnings (Accumulated Deficit) | -1487.85 | -1209.86 | -906.197 | -739.786 | -620.426 |
Other Equity, Total | -0.69874 | -0.28224 | -0.25615 | 0.47261 | -0.52887 |
Total Liabilities & Shareholders’ Equity | 348.533 | 495.941 | 539.772 | 143.952 | 131.113 |
Total Common Shares Outstanding | 253.091 | 217.383 | 186.851 | 101.361 | 97.2258 |
Total Preferred Shares Outstanding | 0.00001 | 0.00001 | 0.00001 | 0.00002 | 0.00002 |
Long Term Debt | 16.6148 | 14.9597 | 18.6558 | 77.0229 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 233.896 | 315.243 | 350.208 | 416.185 | 399.907 |
Cash and Short Term Investments | 223.751 | 252.999 | 281.883 | 348.125 | 360.394 |
Cash & Equivalents | 28.2381 | 46.3294 | 21.9882 | 41.1019 | 59.0095 |
Short Term Investments | 195.513 | 206.669 | 259.895 | 307.023 | 301.384 |
Total Receivables, Net | 5.03511 | 11.7382 | 10.0807 | 11.3715 | 7.4908 |
Accounts Receivable - Trade, Net | 0.0733 | 1.70173 | 2.44287 | 4.48264 | 4.00368 |
Prepaid Expenses | 5.11017 | 50.5057 | 58.2442 | 56.6886 | 32.0223 |
Total Assets | 266.583 | 348.533 | 391.968 | 459.399 | 445.511 |
Property/Plant/Equipment, Total - Net | 16.8489 | 17.9562 | 26.1652 | 27.126 | 27.9484 |
Goodwill, Net | 10.5134 | 10.5134 | 10.5134 | 10.5134 | 10.5134 |
Intangibles, Net | 2.04778 | 2.12986 | 2.24944 | 2.36903 | 2.49959 |
Long Term Investments | 2.62378 | 2.00714 | 2.12999 | 2.43505 | 3.36907 |
Other Long Term Assets, Total | 0.65252 | 0.68404 | 0.70199 | 0.77014 | 1.2738 |
Total Current Liabilities | 55.1511 | 96.8681 | 94.9147 | 131.064 | 59.3597 |
Payable/Accrued | 1.41727 | 80.9073 | 75.7816 | 106.354 | 39.5228 |
Accrued Expenses | 21.9336 | 13.3981 | 16.3067 | 12.8605 | 14.5007 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 4.211 | 2.5627 | 2.82645 | 11.8495 | 5.33615 |
Total Liabilities | 67.369 | 126.171 | 125.271 | 161.728 | 90.4261 |
Total Long Term Debt | 0 | 16.6148 | 16.3013 | 16.5214 | 16.2079 |
Long Term Debt | 0 | 16.6148 | 16.3013 | 16.5214 | 16.2079 |
Deferred Income Tax | 0.03205 | 0.03205 | 0.03205 | 0.03205 | 0.03205 |
Other Liabilities, Total | 12.1859 | 12.6556 | 14.0227 | 14.1104 | 14.8265 |
Total Equity | 199.214 | 222.363 | 266.697 | 297.671 | 355.085 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.26274 | 0.25309 | 0.24948 | 0.2475 | 0.22651 |
Additional Paid-In Capital | 1728.03 | 1710.66 | 1700.72 | 1693.67 | 1642.42 |
Retained Earnings (Accumulated Deficit) | -1528.5 | -1487.85 | -1433.38 | -1395.6 | -1287.1 |
Other Equity, Total | -0.5828 | -0.69874 | -0.88521 | -0.64966 | -0.45789 |
Total Liabilities & Shareholders’ Equity | 266.583 | 348.533 | 391.968 | 459.399 | 445.511 |
Total Common Shares Outstanding | 262.739 | 253.091 | 249.485 | 247.505 | 226.511 |
Total Preferred Shares Outstanding | 0.00001 | 0.00001 | 0.00001 | 0.00001 | 0.00001 |
Accounts Payable | 11.1944 | ||||
Current Port. of LT Debt/Capital Leases | 16.3948 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -279.818 | -303.659 | -167.475 | -120.552 | -96.9678 |
Cash From Operating Activities | -216.215 | -215.709 | -177.979 | -97.8501 | -73.5502 |
Cash From Operating Activities | 3.65671 | 3.0401 | 3.039 | 3.59839 | 3.74718 |
Amortization | 0.49649 | 0.52042 | 0.54708 | 1.06629 | 1.24958 |
Deferred Taxes | 0 | 0 | 0.0054 | 0 | |
Non-Cash Items | 39.6153 | 34.0382 | 56.9816 | 21.5747 | 13.3131 |
Changes in Working Capital | 19.8342 | 50.3515 | -71.0718 | -3.54312 | 5.10778 |
Cash From Investing Activities | 109.586 | -175.344 | -58.7957 | -9.045 | 42.4199 |
Capital Expenditures | -0.96915 | -1.23101 | -1.52067 | -0.98793 | -2.08502 |
Other Investing Cash Flow Items, Total | 110.555 | -174.113 | -57.2751 | -8.05707 | 44.5049 |
Cash From Financing Activities | 81.8407 | 211.499 | 465.28 | 105.398 | 31.0373 |
Financing Cash Flow Items | 0 | 0 | 2.37997 | -0.35463 | 0 |
Issuance (Retirement) of Stock, Net | 81.8407 | 211.499 | 462.728 | 8.3086 | 31.0373 |
Foreign Exchange Effects | -0.02556 | -0.03013 | 0.02721 | ||
Net Change in Cash | -24.8144 | -179.584 | 228.532 | -1.49754 | -0.09295 |
Cash Interest Paid | 1.06698 | 1.0778 | 4.62476 | 2.71759 | |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0.17162 | 97.4436 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -40.6493 | -279.818 | -225.355 | -187.571 | -79.0737 |
Cash From Operating Activities | -36.6645 | -216.215 | -179.875 | -112.41 | -61.8821 |
Cash From Operating Activities | 0.70738 | 3.65671 | 2.77667 | 1.86996 | 0.92938 |
Amortization | 0.08208 | 0.49649 | 0.37691 | 0.25733 | 0.12677 |
Non-Cash Items | 1.7177 | 39.6153 | 35.4049 | 29.4844 | 15.7913 |
Cash Interest Paid | 0.53349 | 1.06698 | 1.06698 | 0.53349 | 0.53349 |
Changes in Working Capital | 1.47767 | 19.8342 | 6.92106 | 43.5492 | 0.3442 |
Cash From Investing Activities | 18.9999 | 109.586 | 55.585 | 11.0283 | 21.3323 |
Capital Expenditures | -0.29698 | -0.96915 | -0.80404 | -0.71721 | 0 |
Other Investing Cash Flow Items, Total | 19.2969 | 110.555 | 56.3891 | 11.7456 | 21.3323 |
Cash From Financing Activities | -0.4247 | 81.8407 | 75.1727 | 71.3612 | 28.422 |
Financing Cash Flow Items | 0 | ||||
Issuance (Retirement) of Stock, Net | -0.4247 | 81.8407 | 75.1727 | 71.3612 | 28.422 |
Foreign Exchange Effects | -0.00192 | -0.02556 | -0.0379 | -0.02134 | -0.00656 |
Net Change in Cash | -18.0912 | -24.8144 | -49.1555 | -30.0419 | -12.1343 |
Issuance (Retirement) of Debt, Net | 0 | ||||
Deferred Taxes |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.4859 | 20067883 | 1833565 | 2023-06-30 | LOW |
D. E. Shaw & Co., L.P. | Hedge Fund | 2.8358 | 7602133 | 983289 | 2023-06-30 | HIGH |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.2258 | 5966835 | -13954601 | 2023-06-30 | LOW |
Renaissance Technologies LLC | Hedge Fund | 2.0279 | 5436281 | 2795981 | 2023-06-30 | HIGH |
Millennium Management LLC | Hedge Fund | 1.9921 | 5340253 | 5340253 | 2023-06-30 | HIGH |
Jane Street Capital, L.L.C. | Research Firm | 1.1922 | 3196081 | 2261961 | 2023-06-30 | HIGH |
JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 1.1191 | 3000096 | -64550 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.0673 | 2861243 | -2315538 | 2023-06-30 | LOW |
Two Sigma Investments, LP | Hedge Fund | 0.8909 | 2388228 | 2367628 | 2023-06-30 | HIGH |
Kim (Jong Joseph Ph.D.) | Individual Investor | 0.8751 | 2346000 | 0 | 2023-03-17 | LOW |
Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 0.801 | 2147319 | 969218 | 2023-06-30 | HIGH |
GMT Capital Corp. | Hedge Fund | 0.5646 | 1513500 | 1513500 | 2023-06-30 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.4704 | 1260963 | -501449 | 2023-06-30 | LOW |
Qube Research & Technologies Ltd | Hedge Fund | 0.3522 | 944190 | 549920 | 2023-06-30 | HIGH |
Weiner (David B) | Individual Investor | 0.3466 | 929124 | 19000 | 2023-05-16 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3273 | 877447 | -27034933 | 2023-06-30 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.2825 | 757413 | -115730 | 2023-06-30 | HIGH |
BofA Global Research (US) | Research Firm | 0.2499 | 669960 | -2850667 | 2023-06-30 | LOW |
Y-Intercept (Hong Kong) Ltd | Investment Advisor | 0.2364 | 633613 | 633613 | 2023-06-30 | HIGH |
Tudor Investment Corporation | Hedge Fund | 0.2065 | 553484 | 418664 | 2023-06-30 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Inovio Pharmaceuticals Company profile
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system''s tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; QIAGEN N.V.; Coalition for Epidemic Preparedness Innovations; and Beijing Advaccine Biotechnology Co. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.Industry: | Biotechnology & Medical Research (NEC) |
6769 Mesa Ridge Rd.
92121
Income Statement
- Annual
- Quarterly
News

How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com